Repackaging or Combining Propofol Drug Products During the COVID-19 Public Health Emergency

Updated 4/23/2020

In order to mitigate reported drug shortages of propofol, the State of Ohio Board of Pharmacy has adopted the following resolution on the repackaging or combining propofol drug products during the COVID-19 public health emergency.

This guidance is being issued in accordance with a Board resolution adopted on March 2, 2020.

The Board hereby adopts the following FDA policy for Ohio-licensed pharmacies, repackers, and outsourcing facilities on the repackaging or combining propofol drug products during the COVID-19 public health emergency:

- **Temporary Policy on Repackaging or Combining Propofol Drug Products During the COVID-19 Public Health Emergency**

This resolution shall remain in effect for no longer than the duration of the public health emergency related to COVID-19 declared by HHS, including any renewals made by the HHS Secretary in accordance with section 319(a)(2) of the Public Health Service Act (42 U.S.C. 247d(a)(2)).